Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.30451
Abstract: The approach to treatment of relapsing-remitting multiple sclerosis (RRMS) is rapidly evolving, with more than 15 disease-modifying therapies (DMTs) currently licensed for adults. Current treatment algorithms in children with multiple sclerosis (MS) remain heavily reliant… read more here.
Keywords: sclerosis; future pediatric; considering future; trial ... See more keywords